EGFR and neoplasm: For example, activating mutations in the RAS genes (KRAS/NRAS) renders a tumor unresponsive to therapy with monoclonal antibodies against the epidermal growth factor receptor (EGFR) (cetuximab, panitumumab), which is effective only in the absence of such mutations (RAS wild-type).